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When should you suspect 
community-acquired MRSA? 
How should you treat it?
Evidence-based answer
There are no clinical or epidemiologic 
features that will help you to clearly 
distinguish community-acquired 
methicillin-resistant Staphylococcus 
aureus infections (CA-MRSA) from 
methicillin-sensitive (CA-MSSA) infections 
(strength of recommendation [SOR]: B, 
prospective cohort studies). 
 Incision and drainage is the primary 
therapy for purulent skin and soft tissue 
infections (SOR: B, randomized, controlled 
clinical trials [RCTs]). There are inadequate 
data evaluating the role of oral antibiotics 
for MRSA (SOR: B, single RCT).
❚ Evidence summary
Two prospective cohort studies have 
looked at the usefulness of clinical char-
acteristics to help differentiate MRSA 
from MSSA infections. The studies—a 
2002 observational study of 144 children 
and a 2007 study of 180 consecutively 
enrolled adults—found no clear distin-
guishing features for MRSA.1,2 They did 
note some commonly associated risk fac-
tors, however (TABLE).2,3 
Abscess formation was the most 
common presentation of CA-MRSA, 
followed by purulent cellulitis.3,4 The 
prevalence and incidence of nonpurulent 
CA-MRSA is not well defi ned. 
Best treatment bet:
Incision and drainage
Incision and drainage remains the main-
stay of abscess treatment.3,5 A 2007 RCT 
of 166 indigent, inner-city patients with 
confi rmed MRSA investigated combin-
ing incision and drainage with 7 days of 
therapy using either cephalexin or pla-
cebo. The primary outcome was clinical 
cure or failure 7 days after incision and 
drainage. The trial found no advantage 
to adding antibiotics; MRSA would likely 
be resistant to cephalexin in any case.6 
A 2006 summary from Clinical Evi-
dence found no RCT support for any 
outpatient antibiotic.7 No evidence exists 
that intranasal mupirocin or antiseptic 
body washes reduce the recurrence rate.7 
We found no studies evaluating the opti-
mal treatment of purulent skin and soft 
tissue infections without abscesses. 
Avoid ﬂ uoroquinolones
MRSA isolates demonstrate a high resis-
tance to fl uoroquinolones, so this class of 
drugs isn’t recommended.3 
Recommendations
The Centers for Disease Control and Pre-
vention (CDC) recommends the follow-
ing treatment for CA-MRSA: 
•  drain all abscesses; incision and 
drainage alone suffi ces for immu-
nocompetent patients 
•  for other patients, consider adjunct 
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treatment with clindamycin, trim-
ethoprim and sulfamethoxazole, 
tetracyclines, or linezolid. 
The CDC also recommends consult-
ing an infectious disease specialist before 
using linezolid and avoiding fl uoroqui-
nolone and macrolide antibiotics because 
resistance develops rapidly.8 Rifampin 
can be used in combination with other 
standard treatments.8
The CDC doesn’t recommend treat-
ing nonpurulent skin infections with 
CA-MRSA-specifi c antibiotics. These 
infections are generally caused by Strep-
tococcus pyogenes and remain sensitive 
to β-lactam antibiotics. When the com-
munity prevalence of CA-MRSA is low, a 
β-lactam antibiotic can be used with close 
follow-up.8 
The Infectious Diseases Society of 
America recommends incision and drain-
age for abscesses and treatment with 
CA-MRSA-specifi c antibiotics for puru-
lent skin infections.9 ■
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Is it MRSA? A look at the odds
RISK FACTOR OR (95% CI)*
Antibiotics in past month 2.4 (1.4-4.1)
Abscess 1.8 (1.0-3.1)
Reported spider bite 2.8 (1.5-5.3)
Underlying illness 0.3 (0.2-0.6)
History of MRSA infection 3.3 (1.2-10.1)
Close contact with a person with a similar infection 3.4 (1.5-8.1)
Older age (odds ratio per decade of life) 0.9 (0.9-1)
Snorting or smoking illegal drugs 2.9 (1.2-6.8)
Incarceration within previous 12 months 2.8 (1.1-7.3)
Presentation with a nonskin infection 0.3 (0.1-0.8)
CI, confi dence interval; MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio. 
*Odds ratio of MRSA vs methicillin-sensitive Staphylococcus aureus or another 
bacterium.
Source: Miller LG, et al2 and Moran GJ, et al.3
TABLE
Abscess formation
is the most 
common 
presentation of 
CA-MRSA, 
followed by 
purulent cellulitis.
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